What “Research Chemical” Actually Means

The phrase has no regulatory home

Open FDA's human drug compounding framework and substances are sorted by a small number of tests: whether the substance complies with an applicable United States Pharmacopeia or National Formulary monograph, whether it is a component of an FDA-approved drug product, and whether it appears on the 503A bulks list¹. Outsourcing facilities work from a parallel test built around the 503B bulks list and clinical need².

"Research chemical" is not one of those categories, and it is not a status a substance can hold. It is a phrase printed by a seller.

What the disclaimer is doing

A label reading "for research use only" or "not for human consumption" is not a statement about the molecule. It is a statement about the seller's declared intent, and it is doing two jobs at once.

It positions the sale outside the drug framework, where labelling, manufacturing and reporting obligations attach.

It transfers the question of what the substance is, and whether it is safe, from the seller to the buyer.

Nothing in that phrase describes purity, identity, sterility, endotoxin content or storage. Those are the things a label on an approved drug is required to stand behind, and they are exactly what is absent here.

FDA has published on this exact group of substances

This is the part most readers have never seen, and it is remarkably specific.

FDA maintains a page describing bulk drug substances that were nominated for use in compounding and placed in category 2 — the tier for substances where the agency identified significant safety risks pending further evaluation. As of August 2026 that page was marked current as of 22 April 2026³.

The live category 2 table lists 14 substances. Five are peptides or growth-hormone secretagogues: growth hormone releasing peptide-2 for injectable and nasal routes, growth hormone releasing peptide-6, ibutamoren mesylate, ipamorelin acetate, and kisspeptin-10³.

Below that table sits a second list, of bulk drug substances previously in category 2 whose nominations were withdrawn by the nominators. It runs to 17 entries, and it is a roll-call of the compounds sold as research chemicals: AOD-9604, BPC-157, cathelicidin LL-37, CJC-1295, dihexa acetate, emideltide (DSIP), epitalon, GHK-Cu for injectable routes, ipamorelin acetate, KPV, pegylated mechano growth factor, melanotan II, MOTS-c, selank acetate, semax, thymosin alpha-1, and thymosin beta-4 fragment LKKTETQ, also known as TB-500³.

The detail people get wrong

Those 17 are on a withdrawn list. Saying "BPC-157 is a category 2 substance" in August 2026 is not accurate — it was placed there, and the nomination was withdrawn by whoever submitted it.

What did not go away is the text FDA published about each one. For BPC-157 the agency's stated concern is that compounded drugs containing it may pose risk for immunogenicity for certain routes of administration and may have complexities with regard to peptide-related impurities and active pharmaceutical ingredient characterisation, and that FDA has identified no, or only limited, safety-related information for the proposed routes of administration, so the agency lacks sufficient information to know whether the drug would cause harm when administered to humans³.

For the thymosin beta-4 fragment, FDA's published note goes further: the agency has not identified any human exposure data for drug products containing it³.

Read the whole list and one phrase recurs across entry after entry — immunogenicity risk from aggregation and peptide-related impurities, plus the complexity of characterising the active ingredient. That is a manufacturing statement as much as a pharmacology one. Our pages on BPC-157 and TB-500 work through what the trial record adds to it.

What is missing when there is no approved label

No established identity. Nothing certifies that the vial contains the sequence on the label.

No established purity specification. There is no monograph to fail.

No batch traceability. If something goes wrong, there is no lot to trace it to.

No storage or stability data. Peptides are not indifferent to heat, and nothing here has a shelf-life anyone has validated.

No adverse-event pathway. Nobody is obliged to collect or report what happens next.

The one thing that has been measured

An analytical study of misbranded and adulterated drugs sold over the internet examined products marketed as TB500 and TB1000 and reported that their content is not systematically consistent with the products' own former descriptions⁴.

That is a finding about the supply chain rather than about the peptide. It is also the reason that any anecdote, dose or protocol circulating for a research-chemical peptide is an anecdote about an unidentified substance.

Where the peer-reviewed literature has landed

A 2026 review of approved and unapproved peptide therapies for musculoskeletal injury and athletic performance groups these compounds together and concludes that rigorous human safety data remain scarce, with potential for serious harm to patients⁵.

A 2026 orthopaedic primer on injectable peptide therapy reaches a compatible conclusion from the clinical side: information regarding indications, dosing, frequency and duration of treatment remains unknown for the injectable peptides it examined⁶.

Neither review says these molecules are inert. Both say the human evidence is not there yet, which is a different and more useful statement.

How to talk about these compounds accurately

Say "unapproved" rather than "research chemical". One is a regulatory fact; the other is a sales category.

Say what the registry holds, with a count and a date, rather than saying nothing has been studied.

Say what FDA published, and say whether the nomination that prompted it was later withdrawn.

Say that the identity of the material is unestablished, because for this class it demonstrably is — and that makes every downstream claim about it provisional. The next question is what a certificate of analysis can and cannot fix.